Genocea Biosciences Inc (NASDAQ:GNCA) was the target of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,324,729 shares, a decrease of 46.0% from the February 15th total of 2,451,386 shares. Based on an average daily volume of 729,413 shares, the days-to-cover ratio is currently 1.8 days. Approximately 6.4% of the shares of the company are short sold.
Shares of Genocea Biosciences (NASDAQ:GNCA) opened at $1.21 on Tuesday. Genocea Biosciences has a 1 year low of $0.79 and a 1 year high of $7.29. The firm has a market capitalization of $99.34, a price-to-earnings ratio of -0.61 and a beta of 1.31. The company has a debt-to-equity ratio of -1.26, a current ratio of 0.83 and a quick ratio of 0.83.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03. equities research analysts anticipate that Genocea Biosciences will post -0.59 EPS for the current fiscal year.
A number of brokerages recently commented on GNCA. Cantor Fitzgerald set a $5.00 target price on Genocea Biosciences and gave the company a “buy” rating in a research note on Sunday. Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. HC Wainwright began coverage on Genocea Biosciences in a research note on Thursday, March 8th. They issued a “buy” rating and a $5.00 target price for the company. Robert W. Baird began coverage on Genocea Biosciences in a research report on Monday, February 12th. They issued an “outperform” rating and a $3.00 price target on the stock. Finally, Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Genocea Biosciences currently has a consensus rating of “Buy” and an average price target of $4.41.
ILLEGAL ACTIVITY WARNING: “Genocea Biosciences Inc (GNCA) Short Interest Update” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/03/13/genocea-biosciences-inc-gnca-short-interest-update.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.